Report
Guy Sips ...
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Wim Hoste

Morning Note: AVTX NA, IBAB BB, KDS NA, KPN NA, RES BB

Avantium: Offtake commitments for >50% of FDCA plant
IBA: Selected for Proteus One in Florida
Kiadis: FY20 results: end of the line
KPN: Stonepeak and EQT are preparing bid for KPN
Resilux: Conditional offtake agreement with Avantium
Underlyings
Avantium NV

Avantium NV Formerly known as Avantium Holding BV. Avantium NV, formerly Avantium Holding BV, is a company based in the Netherlands engaged in environmental research and development (R&D). The Company develops chemical technologies and production processes to convert bio-based feedstock into sustainable products. The Company's business comprises three segments: Catalysis, Renewable Chemistries, and YXY. Catalysis segment provides catalysis R&D services and systems to chemical, refinery and energy companies, utilizing its Flowrence Technology Platform to devise the appropriate catalyst testing solutions. Renewable Chemistries is the development division with a portfolio of projects focusing on the conversion of biomass to chemical building blocks and plastic materials. The YXY segment comprises the activities of Syviana, the joint venture with BASF SE. The YXY technology is used to convert plant-based sugars into chemical building blocks for plastics, such as polymer polyethylenefuranoate (PEF), and other applications.

Ion Beam Applications SA

IBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.

Kiadis Pharma

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Co.' lead product ATIR101 is being tested using a single-dose regimen in patients with blood cancer who have not found a matching donor and where a partially matched (haploidentical) family member is used as donor for HSCT.

Resilux N.V.

Resilux is engaged in the production of PET (polyethylene teraphthalate) packaging in the form of preforms and bottles. The preforms are blown into bottles by Co. or by the customer, and then filled with water, soft drinks, edible oils, ketchup, detergents, milk, beer, fruit juices, etc. Co. produces preforms for many applications and in various weights, colors and forms. Preforms and bottles are produced for both single use and multiple use. Co. offers various solutions for barrier-sensitive products.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Guy Sips

Lenny Van Steenhuyse

Ruben Devos

Wim Hoste

Other Reports on these Companies
Other Reports from KBC Securities
Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Sharad Kumar S.P
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch